Immix Biopharma says NEXICART-2 interim data show 89% complete response rate for NXC-201 in relapsed/refractory AL amyloidosis

• Immix Biopharma reported interim trial results for NXC-201 in relapsed or refractory AL amyloidosis, showing strong responses across patients.
• Several additional patients were already disease-negative in bone marrow, suggesting more could convert to complete remission over time.
• No relapses have been seen so far among patients who achieved deep responses, supporting durability expectations.
• The company flagged no neurotoxicity or enterocolitis to date, strengthening the safety profile for a one-time treatment approach.
• Final NEXICART-2 readout and a BLA submission are planned for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290700PRIMZONEFULLFEED9835894) on September 29, 2026, and is solely responsible for the information contained therein.